APA (7th ed.) Citation

K, C., L, L., W, W., MGM, v. R., Y, S., MG, P., . . . J, V. (2026). Vaccine-induced seropositivity/seroreactivity (VISP/R) on common HIV screening assays after vaccination with investigational adenovirus vector-based mosaic HIV regimens in clinical trials. Vaccine, 79, 128500. https://doi.org/10.1016/j.vaccine.2026.128500

Chicago Style (17th ed.) Citation

K, Callewaert, Lavreys L, Willems W, van Rosmalen MGM, Salzgeber Y, Pau MG, Oriol Mathieu V, Hartnett J, and Vingerhoets J. "Vaccine-induced Seropositivity/seroreactivity (VISP/R) on Common HIV Screening Assays After Vaccination with Investigational Adenovirus Vector-based Mosaic HIV Regimens in Clinical Trials." Vaccine 79 (2026): 128500. https://doi.org/10.1016/j.vaccine.2026.128500.

MLA (9th ed.) Citation

K, Callewaert, et al. "Vaccine-induced Seropositivity/seroreactivity (VISP/R) on Common HIV Screening Assays After Vaccination with Investigational Adenovirus Vector-based Mosaic HIV Regimens in Clinical Trials." Vaccine, vol. 79, 2026, p. 128500, https://doi.org/10.1016/j.vaccine.2026.128500.